Active Ingredient History
Rigosertib is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 1/Phase 2)
Anemia (Phase 2)
Anemia, Refractory (Phase 3)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Epidermolysis Bullosa (Phase 1)
Epidermolysis Bullosa Dystrophica (Phase 1/Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Leukemia (Phase 2)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Lung Neoplasms (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 3)
Penile Neoplasms (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 2)
Rectal Neoplasms (Phase 2)
Splenomegaly (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Thrombocytopenia (Phase 3)
Trisomy (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue